MONOCLONAL ANTIBODY, BIOLOGIC
Adbry is a prescription biologic drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe atopic dermatitis whose disease isn’t controlled with topical prescription therapies or for whom those therapies aren’t suitable. Adbry is also referred to by its drug name, tralokinumab-ldrm.
Adbry is a member of a class of drugs called monoclonal antibodies. Scientists believe the drug works by blocking a type of protein called interleukin-13 (IL-13). IL-13 is produced by the immune system and may contribute to inflammatory processes and decreased skin-barrier functioning in atopic dermatitis.
How do I take it?
Adbry is taken as a subcutaneous (under the skin) injection. The recommended dosage is an initial dose of 600 milligrams (four 150 milligram injections). This is followed by 300 milligrams (two 150 milligram injections) once every other week.
A dosage of 300 milligrams every four weeks may be considered for people who weigh less than 100 kilograms (about 220 lbs) who’ve achieved clear or almost clear skin after 16 weeks of treatment.
Prior to starting Adbry, complete all age-appropriate vaccinations as recommended by current immunization guidelines
The FDA-approved label for Adbry lists common side effects including upper respiratory tract infections, conjunctivitis (pink eye), injection site reactions, and eosinophilia (when your body produces too many eosinophils, a type of white blood cell).
Rare but serious side effects listed for Adbry include hypersensitivity reactions, which include anaphylaxis (severe allergic reaction) and angioedema (swelling of deep layers of the skin); conjunctivitis (pink eye) and keratitis (inflammation of the cornea of the eye); parasitic (helminth) infection; and risk of infection with live vaccines.
For more details about this treatment, visit:
Prescribing Information: Adbry (Tralokinumab-Ldrm) Injection, for Subcutaneous Use — LEO Pharma
FAQ — Adbry (Tralokinumab-ldrm) — National Eczema Association